Display options
Cite
Ulahannan SV, Rahma OE, Duffy AG, et al. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepat Oncol. 2015;2(1):39-50doi: 10.2217/hep.14.36.
Ulahannan, S. V., Rahma, O. E., Duffy, A. G., Makarova-Rusher, O. V., Kurtoglu, M., Liewehr, D. J., Steinberg, S. M., & Greten, T. F. (2015). Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepatic oncology, 2(1), 39-50. https://doi.org/10.2217/hep.14.36
Ulahannan, Susanna V, et al. "Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades." Hepatic oncology vol. 2,1 (2015): 39-50. doi: https://doi.org/10.2217/hep.14.36
Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepat Oncol. 2015 Jan 01;2(1):39-50. doi: 10.2217/hep.14.36. PMID: 25685318; PMCID: PMC4326054.
Copy Download .nbib Format: NLM
Share it on

Hepat Oncol. 2015 Jan 01;2(1):39-50. doi: 10.2217/hep.14.36.

Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.

Hepatic oncology

Susanna V Ulahannan, Osama E Rahma, Austin G Duffy, Oxana V Makarova-Rusher, Metin Kurtoglu, David J Liewehr, Seth M Steinberg, Tim F Greten

Affiliations

  1. Gastrointestinal Malignanacies Section, Thoracic & GI-Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
  2. Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.
  3. Biostatistics & Data Management Section, National Cancer Institute, Rockville, MD, USA.

PMID: 25685318 PMCID: PMC4326054 DOI: 10.2217/hep.14.36

Abstract

Biliary tract carcinoma is a rare malignancy. We performed a comprehensive analysis of published prospective clinical trials in advanced biliary tract carcinoma in an attempt to identify active regimens in this setting. We searched PubMed and abstracts presented at the American Society of Clinical Oncology, Gastrointestinal Cancer Symposium, European Society of Medical Oncology and European Cancer Organization conferences for clinical trials in this disease. We found 83 trials. The effect of gemcitabine on overall survival benefit showed a strong trend (p = 0.014) and an improvement in progression-free survival (p = 0.003). Gemcitabine-based regimens containing 5-fluorouracil showed a trend toward an improved overall survival (p = 0.047) relative to platinum agents. Our findings support gemcitabine as the chemotherapy backbone for the treatment of patients with cholangiocarcinoma. Gemcitabine plus 5-fluorouracil combinations warrant further investigations.

Keywords: biliary tract carcinoma; chemotherapy; cholangiocarcinoma; gallbladder carcinoma; treatment

References

  1. Dig Dis Sci. 2008 Feb;53(2):564-70 - PubMed
  2. N Engl J Med. 2010 Apr 8;362(14):1273-81 - PubMed
  3. J Cancer Res Clin Oncol. 2004 Jun;130(6):346-50 - PubMed
  4. Jpn J Clin Oncol. 2010 Dec;40(12):1189-91 - PubMed
  5. Korean J Intern Med. 2013 Sep;28(5):515-24 - PubMed
  6. Am J Clin Oncol. 2007 Jun;30(3):319-24 - PubMed
  7. Ann Oncol. 2005 Feb;16(2):279-81 - PubMed
  8. N Engl J Med. 2008 Jan 3;358(1):36-46 - PubMed
  9. HPB (Oxford). 2010 Aug;12(6):418-26 - PubMed
  10. Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7 - PubMed
  11. BMC Cancer. 2006 May 06;6:121 - PubMed
  12. Ann Surg. 2007 May;245(5):755-62 - PubMed
  13. Cancer. 2005 Jan 1;103(1):111-8 - PubMed
  14. Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9 - PubMed
  15. Oncology. 2003;64(4):475-6 - PubMed
  16. J Clin Oncol. 2010 Oct 20;28(30):4581-6 - PubMed
  17. Cancer Chemother Pharmacol. 2006 May;57(5):647-53 - PubMed
  18. Eur J Cancer. 2013 Jan;49(2):329-35 - PubMed
  19. Cancer. 2005 Dec 15;104(12):2753-8 - PubMed
  20. Am J Clin Oncol. 2004 Dec;27(6):565-9 - PubMed
  21. Ann Oncol. 2003 Jul;14(7):1115-20 - PubMed
  22. J Gastrointest Cancer. 2007;38(2-4):87-94 - PubMed
  23. Curr Treat Options Oncol. 2013 Sep;14(3):337-49 - PubMed
  24. N Engl J Med. 2013 Oct 31;369(18):1691-703 - PubMed
  25. Cancer. 2006 Jan 15;106(2):361-5 - PubMed
  26. Br J Cancer. 2005 May 9;92(9):1650-4 - PubMed
  27. Ann Surg Oncol. 2007 Nov;14(11):3202-9 - PubMed
  28. Ann Oncol. 2001 Feb;12(2):183-6 - PubMed
  29. Hepatogastroenterology. 2008 Jul-Aug;55(85):1380-4 - PubMed
  30. Br J Cancer. 2008 Sep 16;99(6):862-7 - PubMed
  31. Oncology. 2010;78(5-6):356-60 - PubMed
  32. Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34 - PubMed
  33. Anticancer Drugs. 1998 Jun;9(5):393-7 - PubMed
  34. Ann Oncol. 2001 Oct;12(10):1403-6 - PubMed
  35. J Clin Oncol. 2005 Apr 1;23(10):2332-8 - PubMed
  36. Br J Cancer. 2004 Nov 15;91(10):1769-74 - PubMed
  37. Am J Clin Oncol. 2000 Aug;23(4):425-8 - PubMed
  38. Jpn J Clin Oncol. 2005 Aug;35(8):439-43 - PubMed
  39. Jpn J Clin Oncol. 2003 Jul;33(7):353-6 - PubMed
  40. Chemotherapy. 2003 Jun;49(3):154-8 - PubMed
  41. Chemotherapy. 2011;57(3):236-43 - PubMed
  42. Br J Cancer. 2009 Dec 1;101(11):1846-52 - PubMed
  43. Ann Oncol. 1994 Sep;5(7):609-16 - PubMed
  44. Br J Cancer. 2002 Sep 23;87(7):702-4 - PubMed
  45. Ann Oncol. 2006 Jun;17 Suppl 7:vii68-72 - PubMed
  46. Ann Oncol. 2002 Aug;13(8):1192-6 - PubMed
  47. Chemotherapy. 2008;54(6):479-84 - PubMed
  48. N Engl J Med. 1999 Oct 28;341(18):1368-78 - PubMed
  49. Cancer Chemother Pharmacol. 2011 Dec;68(6):1595-602 - PubMed
  50. Am J Clin Oncol. 2006 Apr;29(2):127-31 - PubMed
  51. Ann Oncol. 2008 Jan;19(1):99-103 - PubMed
  52. Br J Cancer. 2004 Apr 19;90(8):1516-20 - PubMed
  53. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  54. Br J Cancer. 2006 Oct 9;95(7):848-52 - PubMed
  55. Br J Cancer. 2007 Mar 26;96(6):896-902 - PubMed
  56. Lancet Oncol. 2012 Feb;13(2):181-8 - PubMed
  57. Br J Cancer. 2004 May 4;90(9):1715-9 - PubMed
  58. Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55 - PubMed
  59. Yonsei Med J. 2005 Aug 31;46(4):526-31 - PubMed
  60. Cancer. 2006 Mar 15;106(6):1339-46 - PubMed
  61. Br J Cancer. 2008 Jan 29;98(2):309-15 - PubMed
  62. Ugeskr Laeger. 2013 Oct 14;175(42):2478-81 - PubMed
  63. Cancer. 2005 Jun 1;103(11):2338-43 - PubMed
  64. J Hepatol. 2004 Mar;40(3):472-7 - PubMed
  65. Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8 - PubMed
  66. Ann Oncol. 2006 Jun;17 Suppl 7:vii73-7 - PubMed
  67. Invest New Drugs. 2004 Apr;22(2):193-8 - PubMed
  68. Eur J Cancer. 2005 Feb;41(3):398-403 - PubMed
  69. Jpn J Clin Oncol. 2005 Feb;35(2):68-73 - PubMed
  70. Crit Rev Oncol Hematol. 2013 Nov;88(2):368-74 - PubMed
  71. Ann Oncol. 1996 Aug;7(6):593-600 - PubMed
  72. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  73. BMC Cancer. 2005 Jun 12;5:61 - PubMed
  74. Cancer. 1978 Jul;42(1):330-5 - PubMed
  75. Cancer. 2007 Sep 15;110(6):1307-12 - PubMed
  76. Cancer Chemother Pharmacol. 2010 Feb;65(3):497-502 - PubMed
  77. Clin Colorectal Cancer. 2002 Aug;2(2):81 - PubMed
  78. Jpn J Clin Oncol. 2007 Nov;37(11):843-51 - PubMed
  79. Am J Clin Oncol. 2003 Apr;26(2):124-6 - PubMed
  80. Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):110-4 - PubMed
  81. J Clin Oncol. 1997 Jun;15(6):2403-13 - PubMed

Publication Types

Grant support